Nestlé ups its bet on Aim­mune’s peanut al­ler­gy drug to $276M as NDA fil­ing looms, ri­val­ry in­ten­si­fies

Nestlé Health Sci­ence is up­ping its bet on Aim­mune Ther­a­peu­tics by $98 mil­lion $AIMT, with its now $276 mil­lion stake in the com­pa­ny giv­ing it 19% of the biotech’s eq­ui­ty.

Al­lied on Aim­mune’s peanut al­ler­gy med, Nestlé is bet­ting big on the biotech af­ter the Phase III ef­fi­ca­cy da­ta point­ed to an NDA fil­ing with the FDA next month. Their time­line projects a po­ten­tial mar­ket launch in H2 of next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA